Literature DB >> 11349046

Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.

K A Jolley1, L Appleby, J C Wright, M Christodoulides, J E Heckels.   

Abstract

The opc gene from Neisseria meningitidis was cloned into the pRSETA vector, and recombinant protein was expressed at high levels in Escherichia coli. The protein was readily purified by affinity chromatography and used for immunization with conventional Al(OH)3 adjuvant or after incorporation into liposomes and Zwittergent micelles. The resulting sera were analyzed for their ability to recognize purified recombinant protein and "native" protein in an enzyme immunoassay with outer membranes and by whole-cell immunofluorescence. Immunization with Al(OH)3 induced high levels of antibodies which reacted with the purified protein but did not recognize whole cells. In contrast, liposomes and micelles induced antibodies which reacted with the native protein in whole cells. The addition of monophosphoryl lipid A (MPLA) to either liposomes or micelle preparations increased the magnitude of the immune response and induced a wider range of immunoglobulin subclasses. This was associated with the ability of the sera to induce complement-mediated killing of the homologous strain. The most effective bactericidal activity was observed with Opc protein incorporated into liposomes containing MPLA. The magnitude of the bactericidal effect was strongly influenced by the level of expression of the Opc protein and was abolished by limited variation in the sequence of the protein expressed by heterologous strains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349046      PMCID: PMC98398          DOI: 10.1128/IAI.69.6.3809-3816.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

1.  Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin.

Authors:  M Christodoulides; E Rattue; J E Heckels
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

2.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

3.  Point mutation in meningococcal por A gene associated with increased endemic disease.

Authors:  B T McGuinness; I N Clarke; P R Lambden; A K Barlow; J T Poolman; D M Jones; J E Heckels
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

4.  Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes.

Authors:  W Jiskoot; T Teerlink; M M Van Hoof; K Bartels; V Kanhai; D J Crommelin; E C Beuvery
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

5.  Topology of outer membrane porins in pathogenic Neisseria spp.

Authors:  P van der Ley; J E Heckels; M Virji; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

6.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

7.  Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway.

Authors:  G Bjune; J K Grønnesby; E A Høiby; O Closs; H Nøkleby
Journal:  NIPH Ann       Date:  1991-12

8.  Variation in the expression of pili and outer membrane protein by Neisseria meningitidis during the course of meningococcal infection.

Authors:  C R Tinsley; J E Heckels
Journal:  J Gen Microbiol       Date:  1986-09

9.  Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations.

Authors:  L M Wetzler; M S Blake; E C Gotschlich
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  15 in total

1.  Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates.

Authors:  Jeannette N Williams; Paul J Skipp; C David O'Connor; Myron Christodoulides; John E Heckels
Journal:  Infect Immun       Date:  2009-09-08       Impact factor: 3.441

2.  Recombinant outer membrane protein C of Aeromonas hydrophila elicits mixed immune response and generates agglutinating antibodies.

Authors:  Sunita Kumari Yadav; Jitendra Kumar Meena; Mahima Sharma; Aparna Dixit
Journal:  Immunol Res       Date:  2016-08       Impact factor: 2.829

3.  The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.

Authors:  Miao-Chiu Hung; Omar Salim; Jeannette N Williams; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

Review 4.  Review of meningococcal group B vaccines.

Authors:  Dan M Granoff
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

5.  Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.

Authors:  Magdalena K Bielecka; Nathalie Devos; Mélanie Gilbert; Miao-Chiu Hung; Vincent Weynants; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2014-12-01       Impact factor: 3.441

6.  Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.

Authors:  M I de Jonge; G Vidarsson; H H van Dijken; P Hoogerhout; L van Alphen; J Dankert; P van der Ley
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 7.  Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Authors:  Dan M Granoff; Sanjay Ram; Peter T Beernink
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

Review 8.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

9.  Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.

Authors:  Meili Shao; Yong Wang; Chunlai Wang; Yang Guo; Yonggang Peng; Jiandong Liu; Guangxing Li; Huifang Liu; Siguo Liu
Journal:  Acta Vet Scand       Date:  2010-09-11       Impact factor: 1.695

10.  A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.

Authors:  Delin Zhu; Jeannette N Williams; Jason Rice; Freda K Stevenson; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.